Fig 5. Mice receiving Ad35.HSV.gD2 and CJ2-gD2 immune serum show partial protection and viral shedding after challenge.

Mice (N = 10/group) received three dilutions (High, Mid, Low) of serum pools from Ad35.HSV.gD2 or CJ2-gD2 immunized mice 3 and 2 days before intravaginal challenge (0.5 ml serum/mouse/day). Serum pools were diluted to equal gD2 ELISA titers before transfer. Control mice received naïve serum pool or active immunization with Ad35.HSV.gD2 (10¹⁰ vp/mouse) 42 and 14 days before challenge. Mice were challenged intravaginally with 200LD₅₀ HSV-2 G strain on day 0. After challenge mice were monitored daily for (a) survival for 21 days. One day before challenge, serum was collected and HSV-2 VNT and gD2 ELISA titers were measured. Logistic regression analysis was performed using (b) HSV-2 VNT (log₂ IC₅₀) versus survival status (0 = dead at day 21; 1 = alive at day 21) and (c) gD2 ELISA titers (log₁₀ EU/mL) versus survival status. Thick black and grey lines depict the regression curves for Ad35.HSV.gD2 and CJ2-gD2, respectively. Thin black lines and thin dotted lines depict the 95% confidence intervals for Ad35.HSV.gD2 and CJ2-gD2, respectively.